StemCell Therapy

An Indian American professor has developed the technology behind the Nanolife Disinfectant Tunnel, which successfully uses silver nano-particles to kill off viral infections.

Kattesh Katti, professor of radiology and director of the Institute of Green Nanotechnology at the University of Missouri in Columbia, Mo., told India-West the technology has been tested successfully on COVID-related viruses. Currently, the 8-foot-long tunnel has been deployed at three locations in Chennai, including the Tirumala Tirupati Temple, where thousands of devotees worship each day.

Indias Prime Minister Narendra Modi has placed an order for more tunnels, according to Katti, which are distributed in India through the company Nanolife.

Katti discovered the effectiveness of silver nano-particles in killing off viruses 20 years ago, and commercialized the technology via a hand sanitizer that uses no alcohol or chemicals. The technology was also being used as a cleaning agent in Indian hospitals, he said.

Then the COVID-19 pandemic hit; Katti and the team at Nanolife re-purposed their technology to address the global crisis, which has killed more than 214,000 people around the world, and infected more than three million people.

India, currently on a nationwide quarantine ordered by Modi in March, has a relatively low rate of infection and death from COVID-19: the country had reported 937 deaths and approximately 30,000 infections as of April 28.

But the countrys overcrowded conditions which make required social distancing difficult could drastically raise the number of deaths from the virus, predict Indian epidemiologists.

A country like India really needs more resources, Katti told India-West. The very high population density makes the pandemic significantly more dangerous, he said.

Unlike other disinfecting tunnels currently used in India and some other countries, Nanolifes disinfectant tunnel uses no harmful chemicals, which could be toxic. The technology is based simply on silver nano-particles, water and a proprietary herb that keeps the particles intact, said Katti, adding that the product is used in very low concentrations in the tunnels.

Prof. Jagat Ram of the Postgraduate Institute of Medical Education and Research, Chandigarh, and Prof. JS Thakur, chairman, Covid-19 Prevention Committee at PGI, have questioned the efficacy of disinfecting tunnels, stating that they provide people with a false sense of security. But the tunnels to which they were referring to use sodium hypochlorite, which is known to have several serious side effects. Nanolifes tunnels have no side effects, according to Katti.

The Government of India has banned the export of COVID-related technology, citing the huge need within the country for such products. Thus, for the moment, the Nanolife Disinfectant Tunnel is limited to deployment in India, but Katti is aiming to eventually bring the device to the U.S.

The Dharwad native said he envisions the Nanolife Disinfectant Tunnel in front of railway stations, airports, office buildings, and other large gathering places. Demand far outweighs production capability at the moment, he told India-West.

According to his bio, green nanotechnology is at the focal point of Katti's approach to pursuing research in nanotechnology and molecular medicine as he strongly believes in the total elimination of toxic chemicals in the production of engineered nanoparticles.

He uses phytochemicals occurring naturally within plants and herbs for nano constructs in a variety of applications.

Originally posted here:
Missouri Indian American Professor Develops Disinfecting Tunnel to Kill Viral Infections Using Silver Nano-particles - India West

Apr 29, 2020 06:57 PM EDT

Researchers have made new inroads into understanding aerosol treatments for asthma to help in improvements of the drug in the future. Such innovation can potentially help asthma patients.

Asthma is a disease of the lungs that affects around 330 million people all over the world. It is a major worldwide health concern. Presently, the best treatment form and preparation available with the most beneficial impact are aerosols inhaled directly into the patient's lungs. It is a challenge for researchers because our current knowledge regarding the microstructure of drugs before being converted to aerosol is quite limited.

Such aerosol preparations arecarrier-based DPI or dry powder inhalers, which must be characterized accurately for particle size distribution, surface roughness, flow properties, and fines contents. It is critical to understand the powder formulation's micro-structure, but before the current research, characterization techniques have not given complete information.

Conventional techniques include optical microscopy or OM and laser diffraction or LD. These techniques are limited because the particles are assumed to be spherical and because they provide varying results based on particle dispersion and orientation.

Scientists from theUniversity of Manchesterhave done research that sheds light on this aspect. Using X-Ray Micro-Computer Tomography (or XCT) scanning, the microstructure of the drug's particles have been quantified to the nano-level or scale.

Researchers revealed this 3D microstructure for the first time. It gives the scientific community, medical researchers, and pharmaceutical companies more understanding regarding the drug's behavior when it is aerosolized.

Dr. Parmesh Gajjar, the research's lead author, said that the team was successful in visualizing a 3-D drug-blend to see the interaction between its active ingredient and its non-drug particles. Such insight is essential in the final step of quality control of drug production. It will enable producers to verify the actual drug content in the medicine and help in coming up with better formulations, and thus improve its effectiveness.

The XCT equipment and instruments that the research team utilized is located at the world-leading HMXIF or the Henry Moseley X-ray Imaging Facility. This facility is housed at the University of Manchester. The facility and equipment are capable of analyzing samples at a resolution as small as 50nm.

The research is very important in obtaining knowledge about asthma inhalation medicines, which need aerosolization for generating particles small enough to be absorbable by the lungs. The project studied particles that are tiny enough to be able to reach into the lung's deepest recesses.

The research's novel technological innovation was one of the papers proposed to be presented at the2020 Respiratory Drug Delivery conference(RDD); it was chosen one of the key presentations at the said global conference. The venue of the conference was initially booked at Palm Springs. Still, due to the coronavirus pandemic and the lockdowns it caused, the organizers first opted to make it an online event instead and has currently been canceled until further notice.

The study was published in theEuropean Journal of Pharmaceutics & Biopharmaceuticsand is entitled "3D Characterisation of Dry Powder Inhaler Formulations: Developing X-Ray Micro Computed Tomography Approaches.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

See the original post:
New Insights in Asthma Medicines May Improve Future Drugs and Treatment - Nature World News

Global Regenerative Medicine Market Added by Report Ocean covers valuable insights based on market valuation, market size, SWOT Analysis, revenue forecast and regional outlook of this industry. The research also presents a precise summary of the industry competitive spectrum, while drawing attention to the growth prospects and expansion plans adopted by key market players.

The global regenerative medicine market report is a comprehensive research study of this business space that has been projected to garner highly appreciable returns by the end of the forecast duration. The report analyzes global regenerative medicine market and provides an insight into pivotal parameters such as market size, sales volume, revenue forecast. The segmentation of the global regenerative medicine market and intrinsic details regarding these segments in addition to the specific drivers fueling the remuneration and commercialization landscape of this business space have also been enumerated in this report.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=43390

In this report, we analyze the Global Regenerative Medicine Market from two aspects.

1. Production In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019.

2. Consumption In terms of consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019.

We also make a prediction of its production and consumption in coming 2020-2026.

At the same time, we classify different regenerative medicine market based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. It also focuses on market influencing factors, competitive landscape, data, trends, information, and exclusive vital statistics of the market.

A brief summary of how the regenerative medicine market will perform has been illustrated in the report. Moreover, crucial specifics such as growth drivers as well as the expected growth rate of the regenerative medicine market during the forecast period are included in the report. The report also details the potential growth aspects along with the restraints of this industry vertical.

Global Regenerative Medicine Market report focuses on various key parameters that include:

Market concentration ratio

Consumption growth rate

Growth rate

Turnover predictions

Industry drivers and major challenges

Recent market trends

Geographical segmentation

Competitive structure

Competitive ranking analysis

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the regenerative medicine market report; it identifies direct or indirect competitors in the market.

Key parameters which define the competitive landscape of the Global Regenerative Medicine Market:

Profit margins

Product sales

Company profile

Product pricing models

Sales geographies

Distribution channels

Industry evaluation for the market contenders

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of regenerative medicine market. The common characters are also being considered for segmentation such as global market share, common interests, worldwide demand and supply of Access Control devices. Moreover, the report compares the production value and growth rate of regenerative medicine market across different geographies.

Unravelling the geographical landscape of the Global Regenerative Medicine Market:

Americas (United States, Canada, Mexico, Brazil)

APAC (China, Japan, Korea, Southeast Asia, India, Australia)

Europe (Germany, France, UK, Italy, Russia, Spain)

Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

The research methodology adopted by analysts to study the market include inputs derived from industry professionals across the value chain and various other secondary research methods, along with primary research as a major tool for market study.

Some of the Major Highlights of TOC covers:

Executive Summary

Global Regenerative Medicine Market Insights

Global Regenerative Medicine Market forecast by different Segments and Regions

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of regenerative medicine market

Key Figures of Major Manufacturers

Development Trend of Analysis of regenerative medicine market

Global Regenerative Medicine Market Trend Analysis

Global Regenerative Medicine Market Size (Volume and Value) Forecast 2020-2026

Marketing Channel

Direct Marketing

Indirect Marketing

Global Regenerative Medicine Market Customers

Market Dynamics

Market Trends

Opportunities

Market Drivers

Challenges

Influence Factors

Methodology/Research Approach

Research Programs/Design

Market Size Estimation

Market Breakdown and Data Triangulation

Data Source

Key Questions Addressed in the Report:

1. Who are the top 10 players operating in the regenerative medicine market?

2. What are the driving factors, restraints, opportunities, and challenges in the regenerative medicine market?

3. What are the current scenario and industry trends in the regenerative medicine market?

4. Which industry and technology can be a potential revenue pocket for market players in the next five years?

5. Who are the visionary leaders, dynamic differentiators, innovators, and emerging players and what are the key strategies adopted by them to strengthen their positions?

6. What are the regenerative medicine market opportunities and threats faced by the vendors in the regenerative medicine market?

7. What are the regenerative medicine market challenges to market growth?

8. Analysis based on historical information along with the current trends to estimate the future of the market

9. Analysis of the impact of constantly changing global market scenarios

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=43390

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or country-based analysis can be provided as a part of customization

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Nick MartinEmail:[emailprotected]

Read this article:
Global Regenerative Medicine Market Industry Analysis and Forecast (2019-2026) by Product type, Application and Region Cole Reports - Cole of Duty

The global Regenerative Medicine market offers a thorough study of all the important aspects of the market. All the factors that are responsible for the growth of the global market are studied in this report. In addition to that, the factors causing hurdles in the path are also studied in the report. For the study of any market it is very important to study some factors such as market trends, revenue growth patterns market shares, demand and supply. In addition, it also covers political and social factors which is likely to affect the growth of the market. Production, market share, revenue rate, key regions and major vendors are some of the vital aspects analysed in the report. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users.

Get sample copy of Regenerative Medicine Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/52

The global Regenerative Medicine market is a detailed research report which covers all the quantitative as well as qualitative aspects about the Regenerative Medicine markets across the globe. The report is also inclusive of different market segmentation, business models and market forecasts. This market analysis enables the manufacturers with impending market trends. A thorough scrutiny of prominent market players or industrialists are vital aspect for planning a business in the market. Also, study about the rivals enables in attaining valuable data about the strategies, companys models for business, revenue growth as well as statistics for the individuals attracted towards the market. This report is very useful for the new entrants as it offers them with the idea about the different approaches towards the market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analysed in the report includes market share, production, key regions, revenue rate as well as key players. This Regenerative Medicine market report also provides the readers with detailed figures at which the Regenerative Medicine market was valued in the historical year and its expected growth in upcoming years. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users. In addition, the report include deep dive analysis of the market, which is one of the most important features of the market.

In addition, the market research industry delivers the detailed analysis of the global Regenerative Medicine market for the estimated forecast period. The market research study delivers deep insights about the different market segments based on the end-use, types and geography. One of the most crucial feature of any report is its geographical segmentation of the market that consists of all the key regions. This section majorly focuses over several developments taking place in the region including substantial development and how are these developments affecting the market. Regional analysis provides a thorough knowledge about the opportunities in business, market status & forecast, possibility of generating revenue, regional market by different end users as well as types and future forecast of upcoming years.

The company profiles also covers the detailed description and segmentation of the companies along the finances which are being covered for the company. The global Regenerative Medicine market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market. Furthermore, several factors such as the emergence of new opportunities is also likely to boost the growth of the market. In addition, the market research provides several detailed analysis for the market which has an impact for the end user.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

View original post here:
Regenerative Medicine Market Analysis by Demand, Applications, End Users, Companies, Sales Prospects, Forthcoming Developments, Business Opportunities...

Dr. Timothy Chan, an immuno-oncology and cancer genomics expert, has been named director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic, according to a news release.

He will lead the new center, which brings together multidisciplinary experts from across the system to advance research and treatment related to immuno-oncology, a rapidly growing field.

"Immunotherapy is the future of research in cancer and various other diseases and Cleveland Clinic has made it a priority by establishing this new center," Dr. Serpil Erzurum, chair of the Clinic's Lerner Research Institute, said in a prepared statement. "The Center for Immunotherapy and Precision Immuno-Oncology will empower clinicians and scientists throughout the enterprise to advance personalized cancer care and breakthrough immunotherapy research at Cleveland Clinic."

The center, which opened this month with the arrival of Chan, was approved in 2019.

Chan joins the system from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he led the Immunogenomics and Precision Oncology Platform and was a tenured professor, the PaineWebber Chair and the Translational Oncology Division chair, according to the release, which notes he is a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University and is on staff in the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute, according to the release.

The Center for Immunotherapy and Precision Immuno-Oncology will have four arms: a Cleveland cell therapy program in collaboration with the Case Comprehensive Cancer Center; immunologic medicine and immuno-oncology labs; a precision immuno-oncology program; and a precision immuno-oncology and developmental therapeutics program.

The center will recruit experts from around the country and globe who specialize in computational science, immunotherapy and cancer immunology, according to the release.

Initially, the new center will have sites focused on immunotherapy research and developmental therapeutics in both Cleveland and the Cleveland Clinic Florida Research and Innovation Center, a 107,000-square-foot laboratory and office space slated to open this summer in Port St. Lucie, Fla. Chan will also collaborate with experts in the new Center for Global and Emerging Pathogens, which was announced last week after a year and a half of planning. This center looks to broaden the understanding of emerging pathogens (from Zika virus to SARS-CoV-2, which causes COVID-19) and expedite critically needed treatments and vaccines.

"Innovation in precision immunotherapy is one of the most exciting areas in cancer research," said Dr. Brian Bolwell, chairman of Taussig Cancer Institute, Cleveland Clinic Cancer Center, in a prepared statement. "The addition of Dr. Chan, a pioneer in cancer genomics, and the new center's focus on research and clinical trials will strengthen our ability to provide advanced treatment options for our patients."

Board certified in radiation oncology and an elected member of the Association of American Physicians, Chan earned his M.D. and Ph.D. in genetics from Johns Hopkins University, where he completed his residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology, according to the release. He has published more than 200 articles in peer-reviewed journals, has made landmark discoveries in his field and has received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018, according to the release.

Read more:
Dr. Timothy Chan to lead Cleveland Clinic's new Center for Immunotherapy and Precision Immuno-Oncology - Crain's Cleveland Business

Recently, the Federal service for supervision in the sphere of health issued the first Russian license for the production of biomedical cell products. She became the owner of a domestic biotechnology company Generium. This will make a significant breakthrough in the field of regenerative medicine.Regenerative medicine is one of the most rapidly growing industries. Its main task is to replace and restore the function of diseased organs or tissues in cases when the natural regenerative capacity of the organism is not able to ensure the restoration and healing of the defect.Methods of regenerative medicine directed on treatment of severe socially significant diseases with high levels of disability, as well as to fill therapeutic niches with high unmet needs.Cellular technology is the most advanced tool of personalized medicine. The presence of a unique infrastructure of Russian biotechnological enterprises making them the center of attraction for the representatives of international pharmaceutical industry and scientists from various fields of science (medics, biologists, physicists, engineers, chemists, IT specialists, mathematicians), and also allows to solve the most challenging public tasks in the field of health. Industrial tissue engineering becomes a reality, said the first Deputy Minister of industry and trade of the Russian Federation Sergey Tsyb.The main segments of the market for regenerative medicine products are tissue therapy and cell therapy biomedical cellular products, which is a cultured human cells. These lines are a driver in research activities of Russian and foreign research centers, which brings together scientists and clinicians around the world.Under the current license it is planned to develop and produce a unique range of autologous, allogeneic and combined BMK, and personalized therapy and diagnostics. Regenerative medicine is not a new technology in medicine and the other medicine. Developing methods for the modification of the cells and edit their genome. There is the prospect of a new therapy, which will focus not only on the regulation of living cells, but also to grow new cells, tissues, structures in our body. With the advent of the first industrial license we understand that regenerative medicine has the potential to become a new efficient branch of the Russian medicine for the treatment of the most severe human diseases incurable by other means, concluded the Dean of the faculty of fundamental medicine of Moscow state University. Lomonosov, academician of RAS AllLod Tkachuk.The world of biotechnology in the field of regenerative medicine are at the stage of explosive growth and investment. A persons ability to manage intra and extracellular processes helps us to create technologies to solve the most difficult tasks in the treatment of patients with serious illnesses or injuries. The countrys first license for industrial production of biomedical cell products gives Russia the opportunity to implement a number of sophisticated cutting edge projects, including to combat coronavirus infection. The country began the era of cellular technologies, said Professor, General Director of JSC GENERIUM Dmitry Kudlay.

More:
Breakthrough in regenerative medicine. Biomedical cell products in Russia - The KXAN 36 News

Like power lines in an electrical grid, long wiry projections that grow outward from neurons -- structures known as axons -- form interconnected communication networks that run from the brain to all parts of the body. But unlike an outage in a power line, which can be fixed, a break in an axon is permanent. Each year thousands of patients confront this reality, facing life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed.

New research by scientists at the Lewis Katz School of Medicine Temple University (LKSOM) shows, however, that gains in functional recovery from these injuries may be possible, thanks to a molecule known as Lin28, which regulates cell growth. In a study published online in the journal Molecular Therapy, the Temple researchers describe the ability of Lin28 -- when expressed above its usual levels -- to fuel axon regrowth in mice with spinal cord injury or optic nerve injury, enabling repair of the body's communication grid.

"Our findings show that Lin28 is a major regulator of axon regeneration and a promising therapeutic target for central nervous system injuries," explained Shuxin Li, MD, PhD, Professor of Anatomy and Cell Biology and in the Shriners Hospitals Pediatric Research Center at the Lewis Katz School of Medicine at Temple University and senior investigator on the new study. The research is the first to demonstrate the regenerative ability of Lin28 upregulation in the injured spinal cord of animals.

"We became interested in Lin28 as a target for neuron regeneration because it acts as a gatekeeper of stem cell activity," said Dr. Li. "It controls the switch that maintains stem cells or allows them to differentiate and potentially contribute to activities such as axon regeneration."

To explore the effects of Lin28 on axon regrowth, Dr. Li and colleagues developed a mouse model in which animals expressed extra Lin28 in some of their tissues. When full-grown, the animals were divided into groups that sustained spinal cord injury or injury to the optic nerve tracts that connect to the retina in the eye.

Another set of adult mice, with normal Lin28 expression and similar injuries, were given injections of a viral vector (a type of carrier) for Lin28 to examine the molecule's direct effects on tissue repair.

Extra Lin28 stimulated long-distance axon regeneration in all instances, though the most dramatic effects were observed following post-injury injection of Lin28. In mice with spinal cord injury, Lin28 injection resulted in the growth of axons to more than three millimeters beyond the area of axon damage, while in animals with optic nerve injury, axons regrew the entire length of the optic nerve tract. Evaluation of walking and sensory abilities after Lin28 treatment revealed significant improvements in coordination and sensation.

"We observed a lot of axon regrowth, which could be very significant clinically, since there currently are no regenerative treatments for spinal cord injury or optic nerve injury," Dr. Li explained.

One of his goals in the near-term is to identify a safe and effective means of getting Lin28 to injured tissues in human patients. To do so, his team of researchers will need to develop a vector, or carrier system for Lin28, that can be injected systemically and then hone in on injured axons to deliver the therapy directly to multiple populations of damaged neurons.

Dr. Li further wants to decipher the molecular details of the Lin28 signaling pathway. "Lin28 associates closely with other growth signaling molecules, and we suspect it uses multiple pathways to regulate cell growth," he explained. These other molecules could potentially be packaged along with Lin28 to aid neuron repair.

Reference:

Fatima M. Nathan, Yosuke Ohtake, Shuo Wang, Xinpei Jiang, Armin Sami, Hua Guo, Feng-Quan Zhou, Shuxin Li. Upregulating Lin28a Promotes Axon Regeneration in Adult Mice with Optic Nerve and Spinal Cord Injury. Molecular Therapy, 2020; DOI: 10.1016/j.ymthe.2020.04.010

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
Scientists Regenerate Neurons in Mice with Spinal Cord Injury and Optic Nerve Damage - Technology Networks

Its still not clear whether Gov. Kate Brown will allow some beauty treatments to resume as part of her decision to allow medical offices to restart elective procedures as early as Friday after more than a monthlong shutdown to stem the spread of the novel coronavirus.

After several days of questioning from The Oregonian/OregonLive, the governors office said Brown didnt intend to allow aesthetician services, medical spas, facial spas, and non-medical massage services to reopen.

But how about doctors or nurse practitioners who provide medical beauty services such as wrinkle reduction?

Spokeswoman Liz Merah said to stay tuned. The state might have additional guidance on opening day, she said.

In a sampling by The Oregonian/OregonLive, some owners believed they werent allowed to reopen, while others were adamant that the governor had given their industry permission to restart anti-aging or aesthetic procedures meant to improve the appearance of the skin or body.

Neighboring governors also have announced the loosening of some restrictions on the medical industry, albeit on a more limited basis than in Oregon.

California Gov. Gavin Newsom said last week that some elective or delayed surgeries -- such as those for cancer or heart problems -- can resume. But Newsom specified cosmetic surgeries are still barred for the time being.

Washingtons Gov. Jay Inslee on Wednesday clarified a previous order restricting nonurgent procedures. He gave health care providers more leeway to resume some of the procedures if delaying them would significantly harm the patient. Inslees direction appears to offer no wiggle room for Botox businesses or other medical spas to reopen.

The confusion in Oregon arose when Brown announced last week that elective, non-urgent medical and dental procedures could restart but didnt offer a specific list of businesses.

She and Dr. Dana Hargunani, the Oregon Health Authoritys chief medical officer, cited examples instead -- including knee surgeries, fertility treatments, dental cleanings, cancer biopsies and hip replacements.

When a reporter asked Hargunani whether cosmetic procedures would be allowed, Hargunani didnt answer directly yes or no. Instead, she left the door open, saying: We are not telling providers exactly what they can or cannot do. But we know that those that are most urgent and necessary are going to be the first on the list.

That might have looked like a green light to many.

Aesthetic Medicine run by Dr. Jerry Darm -- one of the most recognizable faces in Oregons medical beauty industry -- announced his Lake Oswego office will start seeing customers again Monday.

We are reopening May 4th!!!!! Darms Facebook page reads. We are so excited to see our patients and have our staff back. There will be new guidelines for scheduling an appointment but we are feeling very blessed.

The post was met with a flurry of likes and comments such as Awesome!!!! I can wait to see you again and Thats so good to hear the good news.

Darm and the operators of several other medical beauty businesses contacted by the newsroom didnt return messages asking for details about safety protocols and the reason for their decisions to reopen. That includes Key Laser Institute for Cosmetic Regenerative Medicine in outer Southwest Portland, which posted on its Facebook page that its gearing up to see patients again.

Key Laser Institute for Cosmetic Regenerative Medicine's Facebook Post April 27, 2020. (Facebook screenshot)

Some others said its far too soon. Theyre concerned that meager testing means the state doesnt have a handle on the true scope of the problem or the knowledge needed to contain the virus spread through contact tracing.

While Oregon has by far a lower number of known cases and deaths than some other states -- 2,510 positive tests and 103 deaths it also has tested only about one in every 100 residents.

Coronavirus in Oregon: Latest news | Live map tracker |Text alerts | Newsletter

Debora Masten, a certified advanced esthetician in Salem, said she wont start offering customers chemical peels, laser hair removals and other treatments Friday because she doesnt think her services are necessary at this stage in the pandemic.

Its supposed to be stuff you cant put off, Masten said. Im anxious to get open again, too, but I think we have to try as best we can to protect the public.

Masten also noted that like many others who perform a range of treatments, shes not a doctor or nurse practitioner and the governor hasnt given her the OK. Thats even though she sees others who also arent medical professionals gearing up to reopen.

Sharon Griffin, a naturopathic doctor who operates Plush Botox Bar in Northeast Portland, wrote the governor this week urging her to end the confusion.

She asked Brown to specifically require the medical beauty industry to remain shuttered, like so many other businesses ranging from clothing stores to hair salons to dine-in restaurants.

No one really needs Botox in May, but as things stand, theyre gonna get it and possibly a whole lot more in the bargain, Griffin wrote.

She said in an interview that she supports restarting necessary procedures, like her husbands CT scan scheduled next week to diagnose a medical problem.

But she has decided to hold off reopening her own business until at least June 1 to see how the spread of the disease continues to play out, even as she sees competitors around her planning to reopen.

Griffin said shes passionate about what she does -- injectables such as Botox and lip fillers -- but doesnt want to risk the health of customers for procedures that arent life or death matters.

Nobody will die from a wrinkle, Griffin said.

-- Aimee Green; agreen@oregonian.com; @o_aimee

Subscribe to Oregonian/OregonLive newsletters and podcasts for the latest news and top stories.

Read this article:
Confusion reigns over whether Oregonians can receive Botox, other beauty treatments during the coronavirus pa - OregonLive

Last week, we published a briefing that flip-flopped between bad news and good(ish) news. Were balancing todays briefing in a similar vein, tempering the more negative with the more hopeful.

Todays Coronavirus Briefing is 1,078 words and will take you five minutes to read.Click here to sign up for the newsletter.

Bad. Good. Hopeful. Scary. Thank you. Very sad.

Sponsored content

With the COVID-19 outbreak causing an unprecedented impact on the Healthcare Marketing Industry, non-personal promotion has never been more critical. As HCPs are facing this crisis on both professional personal fronts, supporting them through the delivery of your key messaging will be important to the continued care of patients with existing illnesses and chronic conditions.

This is all good, and aspirational news.

Fingers crossed we get to report positively about all of the above, in the coming weeks.

A range of views of our various futures: revolutionary, hopeful, dark and progressive.

A Magic 8-Ball seems like as plausible a barometer for whats to come as anything, or anyone else these days.

Lately, for every Instagram post of someones elaborate meal is an outdoor post of their new-found gardening skills.

If the virus returns this winter, were all going to have to learn vertical indoor farming.

A brief rabbit hole of workplace nostalgia.

See you tomorrow in shoulder pads and feathered hair in quarantine no ones around to see...

Follow this link:
Coronavirus Briefing: Medical breakthroughs, the future of PR, gardens and workplace nostalgia - PRWeek

SAN DIEGO, May 1, 2020 /PRNewswire/ --SunevaMedical,Inc., is proud to announce an exciting new partnership that will further its leadership position in regenerative aesthetics. The exclusive North American distributorship for Sinclair Pharma's innovative Silhouette Instalift sutures will expand Suneva Medical's aesthetic portfolio that addresses the growing market demand for natural and minimally invasive alternatives in aesthetics.

"We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio," saysPat Altavilla, CEO, Suneva Medical. "These unique sutures fit perfectly as they can provide immediate lift to sagging cheeks and, like Bellafill, can activate the patient's natural collagen production over time."

"With Suneva Medical, we have a partnership with a company that has strong commercial presence in the U.S. while giving us the ability to expand our footprint in the North American market," says Chris Spooner, CEO Sinclair Pharma.

To learn more about Suneva Medical and upcoming news from the aesthetics company, please visitwww.SunevaMedical.com.

About Suneva Medical, Inc.Suneva Medical, Inc.headquartered inSan Diego, CAis a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva Medical offers a portfolio of best-in-class products that include Bellafill, the only FDA approved 5-year filler, Puregraft, a unique fat grafting system and Amplifine, an innovative high density platelet rich plasma (PRP) get tube.For more information, visitwww.sunevamedical.com.

About Sinclair PharmaSinclair Pharma is a fully owned subsidiary of Huadong Medicine Limited and headquartered in London, UK. The company operates in the fast growth, global aesthetics market and has built a strong portfolio of differentiated, complementary aesthetics technologies, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Group has an established sales and marketing presence in the leading EU markets, Brazil, Mexico, UAE and South Korea and a network of international distributors. For more information, visit http://www.sinclairpharma.com.

More:
Suneva Medical Increases Its Leadership in Regenerative Aesthetics with New Partnership - WFMZ Allentown

Mercy Plastic Surgery

1229 E. Seminole Suite 340, Springfield, MO |417-820-9330Theres a new member of the team at Mercy Plastic Surgery! Dr. Raghu Nandan is new to Springfield, but not to the operating room. Dr. Nandan is Board Eligible since completing his plastic surgery training at Johns Hopkins University in Baltimore after general surgery with the University of Arizona. Mercy was glad to welcome him in August of 2019.

Dr. Nandan offers head-to-toe care for his patients in Mercys high-quality medical facilitieshe specializes in breast reconstructions and augmentations, cosmetic injections, complex facial plastic surgery, scar revisions, tummy tucks and liposuction. He also assists in the care of breast cancer and melanoma patients.

When asked what he loves most about his work, Dr. Nandan says that he enjoys the opportunity to spend time with his patients, listening to their needs. He believes that by listening to patients, he can connect with them to better understand the best way to help them get the outcome they are looking for. Making positive changes in peoples lives, restoring their form and function and improving their quality of life gives him joy the fact that they can feel more confident is the best part of his career.

Tell us about a time you improved someones life, how you did it and how it felt.I had a teenage patient that was preparing for a leg amputation. Instead, we were able to restore the form and function of his leg. He later walked into the clinic and was showing off his soccer skills to the staff. Being a part of his care was priceless.

Why did you choose to go into your current profession?I chose to be a plastic surgeon to be able to restore form, function and aesthetics, from head to toe. It is one of the very few fields of medicine where you are able to innovate, push the envelope and markedly improve the quality of life and confidence of your patients.

Continue reading here:
Health These Springfield Experts Want to Help You Be Your Best Self When do you feel - 417mag

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about trials of rheumatoid arthritis (RA) drugs to treat COVID-19 patients, how rheumatic patients were affected during the early pandemic days, how the coverage gap closure in Medicare Part D between 2010 and 2019 decreased annual out-of-pocket costs for RA biologics, and an interview about the Autoimmune COVID-19 Project.

The results of a French study found favorable outcomes for COVID-19 patients with moderate to severe pneumonia treated with tocilizumab, a drug commonly prescribed to treat arthritis, according to reports. The French CORIMUNO-TOCI trial was conducted by the public assistance-hospitals of Paris (AP-HP). The results have yet to be published, but the outcomes were reported in a press release and by various news outlets. The main outcome measure was the need for ventilation or death at 14 daysfor which tocilizumab significantly reduced the risk. CORIMUNO is exploring other medicines in COVID-19 patients, too, including sarilumab. Although both are anti-IL-6 drugs, tocilizumab is administered intravenously, while sarilumab is administered subcutaneously. The results of a phase 2 trial studying sarilumab in COVID-19 patients found the drug was not beneficial for patients hospitalized but not on ventilators, according to results from Regeneron and Sanofi, who manufacture the drug.

A study evaluated how patients with rheumatic diseases were impacted by the COVID-19 pandemic during its initial stages in the United States. A total of 7,061 patients were invited to complete the questionnaire, of whom 530 responded. The most common diagnosis among the respondents was rheumatoid arthritis (RA) (61%). Of the 11 patients who met COVID-19 screening criteria, two sought testing unsuccessfully. An additional six patients sought testing, of whom three were successful, and all were negative. About two in five patients (42%) experienced a change to their care during the previous two weeks. Upon qualitative analysis, the researchers unearthed four key themes: emotions in response to the pandemic, perceptions of risks from immunosuppressive medications, protective measures to reduce risk of COVID19 infection, and disruptions in accessing rheumatic disease medications including hydroxychloroquine.

A new study assessed whether the coverage gap closure in Medicare Part D between 2010 and 2019 decreased annual out-of-pocket costs for biologic drugs used to treat RA. Each year, list prices increased for every product assessed in the drug and strength combinations. There were six drugs available for the whole study period; the mean increase for these drugs was 160%. Among the six drugs available for the entirety of the study, the projected mean annual out-of-pocket costs were 34% lower in 2011 than 2010 (2010: $6,108 vs. 2011: $4,026); however, they were only 21% lower by 2019 ($4,801) due to yearly list prices increases. There were four products with higher out-of-pocket costs in 2019 than the first year available that entered the market between 2011 and 2015. The percentage of money spent in the catastrophic phase increased each year for all products studied; the mean was 22% higher in 2019 than in 2010 or the first year the drug was available.

CreakyJoints and the Global Healthy Living Foundation collectively launched the Autoimmune COVID-19 Project, a longitudinal study with the goal of assessing the impact of COVID-19 on patients with multiple sclerosis, arthritis, Crohns and colitis, and vasculitis. DocWire News recently interviewed study lead Shilpa Venkatachalam, PhD, associate director of Patient-Centered Research at CreakyJoints and co-principal investigator of ArthritisPower, about the studys inception, its goals, and more.

Continued here:
Rheum Round-up: Are Arthritis Drugs the Holy Grail of COVID-19?, How The Pandemic Affected Rheumatic Patients, and more - DocWire News

The word arthritis derives from the Latin arthro meaning joint and ritis meaning inflammation.

There are broadly two main types of arthritis although one can classify 100 different types. The two main types are the degenerative (wear and tear) and the inflammatory types of arthritis.

Arthritis can affect any age group, not just the elderly. Juvenile inflammatory arthritis can be a disabling illness in young children.

In the vast majority of cases, degenerative arthritis is primary i.e. with no preceding cause. In rare cases, however, degenerative arthritis may be secondary to a fracture of the joint, infection or inflammation.

Arthritis can affect any joint; but those most commonly affected by degenerative arthritis are the hip, knee, neck and back.

The patient suffers from a variety of symptoms which may develop and progress over time into degenerative arthritis.

In contrast, in inflammatory arthritis, these symptoms may develop suddenly. The symptoms include pain which usually worsens with activity and stiffness mostly in the morning and following inactivity which might be accompanied by swelling. In advanced cases, there will be deformity and muscle-wasting. The symptoms cause lack of function of the joint and disability.

Diagnosis is aided by radiological investigations which, in degenerative disease, show loss of joint space, sclerosis which is whitening of the bones and bony projections called osteophytes. Interestingly, there is not always a direct correlation between the severity of radiological findings and the symptoms described.

Diagnosis is aided by radiological investigations which, in degenerative disease, show loss of joint space, sclerosis which is whitening of the bones and bony projections called osteophytes

Treatment of arthritis broadly falls into four categories:

1. Weight loss for lower limb arthritis, routine and regular exercise and physiotherapy helps build muscle, decrease stiffness, decrease pain and also improve psychological well-being. Cycling, swimming and the cross-trainer are ideal for hip, knee and foot arthritis.

2. Medications include cartilage-nutrient supplements such as glucosamine and chondroitin. Medications including anti-inflammatories shouldnt be prescribed on a long-term basis due to side effects. They should be used to allow the patient to exercise and undertake regular physiotherapy.

3. Other options for treatment include injections. There are principally three types of injections I use. These are not all necessarily adapted for each arthritic joint.

While steroid injections are a mixture of a local anaesthetic and steroid injected directly into the joint, viscosupplementation involves injecting a thick viscous fluid in the joint which is thought to act as a shock absorber.

On the other hand, PrP or platelet rich plasma involves extracting about 15ml of blood from the patient, centrifuging it and injecting the fluid left without the cells into the joint. This plasma contains nutrients and other factors that help regenerate cartilage, prevent its breakdown and decrease inflammation.

4. Surgery remains the best option for those patients who fail to improve with the other options. Different surgical techniques are adapted for different joints but broadly, these may include washout of the joints by keyhole or arthroscopic techniques. Examples of these techniques include excision of the joint (excision arthroplasty) such as the collar bone joint; fusion of the joint (arthrodesis) such as the foot big-toe joint and replacement (arthoplasty).

In the latter, the arthritic joint is excised and replaced by a metal and plastic artificial joint. In fact, most joints in the body may be replaced including the small joints of the hand, wrist, elbow, shoulder and, of course, hip and knee. Although these are fairly major procedures, the benefit they provide to the patients quality of life is tremendous.

Alistair Pace is a consultant orthopaedic surgeon and senior lecturer at the University of Malta.

Independent journalism costs money. Support Times of Malta for the price of a coffee.

Read this article:
How to deal with arthritis - Times of Malta

(BPT) Arthritis joint pain is a daily reality for millions of people in the United States. For some, this pain is temporary due to an injury, but for others, it can be a persistent and even debilitating symptom of arthritis.

Osteoarthritis is the most common form of arthritis, according to the Centers for Disease Control and Prevention, affecting more than 30 million adults in the United States1. About one in four adults report experiencing severe joint pain related to arthritis, and nearly half of adults with arthritis experience persistent pain2.

Whether your arthritis pain is temporary or ongoing, its important to take steps to alleviate discomfort. We may not realize how much joy comes from the simplest everyday movements, until pain gets in the way. Here are four simple tips that may help lessen your arthritis joint pain so you can feel better and keep moving.

1. Use hot and cold therapy

Applying hot and cold compresses to your joints can help provide some much-needed relief. When joints feel stiff, use heat to help them relax and feel more agile. A morning bath or shower can make a world of difference for stiff joints after sleeping. For joint pain that involves swelling and inflammation, look to incorporate cold therapy into your routine. For instance, if your knee is sore and looks puffy, apply a cold compress or bag of frozen veggies wrapped in a towel.

2. Move your body

If you have arthritis symptoms, including wrist, hand or knee pain, the idea of getting up and exercising may seem counterintuitive. However, thoughtfully moving your body helps increase blood flow to joints and stretches muscles and ligaments, which can provide some relief. Regular movement helps increase flexibility while also building muscle, which is important for the health of the joints.

3. Use over-the-counter medicines

If you want an alternative to taking pills to manage pain, there is now an effective topical arthritis pain relief solution available without a prescription. The FDA recently approved Voltaren Arthritis Pain as the first and only full prescription-strength topical nonsteroidal anti-inflammatory (NSAID) gel available over the counter for the treatment of arthritis pain in adults in the hand, wrist, elbow, foot, ankle or knee. Visit http://www.voltarengel.com/what-is-voltaren/ now to preorder Voltaren Arthritis Pain (available nationwide next month). If you order now through May 12, 100% of profits from pre-order will be donated to the Arthritis Foundation to provide virtual care and connection for their patient community*. Additionally, for every donation made to the Arthritis Foundation between May 13 and May 31 in support of its goal to provide virtual care and connection to their patient community and mission, Voltaren will match up to $100,000.

4. Add glucosamine and omega-3s to your diet

Fish oil has been studied for dozens of inflammatory and autoimmune disorders, according to the Arthritis Foundation3. You can get the omega-3s by taking a high-quality fish oil supplement. Look for fish oil options with at least 30% EPA and DHA (both types of omega-3s). According to the Arthritis Foundation, taking up to 2.6 grams EPA/DHA twice a day may help relieve osteoarthritis pain.

If arthritis joint pain is a part of your life, try these simple strategies at home to help movement so you can live a full, healthy life.

More:
Simple tips and tricks to help manage arthritis pain - Defiance Crescent News

Dear family and friends,

I have rheumatoid arthritis (RA), a chronic autoimmune disease. Its not the wear-and-tear type of arthritis you might get with old age. This is different. It affects my whole body and chips away at my well-being. To be honest, Im still figuring it out myself. One thing I do know is that it will affect not just my life, but also yours. I want to help you understand how it feels to be me. If you know the basics, we have a place to start a conversation.

Remember the last time you had the flu? You felt sick and feverish, your body was hurting, and you were so tired that the idea of making a cup of tea or taking a shower was completely overwhelming.

RA makes me feel like that. This illness happens when the immune system malfunctions. Instead of protecting me against infection, it gets confused and attacks tissues and structures in my body. Arthritis in my joints is one of the symptoms, but being an autoimmune disease means it affects my entire body. Thats what makes me feel like I have the flu all the time. Sometimes, it gets better, usually through taking medications, but its no guarantee. RA can flare unpredictably, all my symptoms increasingsometimes a little, sometimes taking over my life. I have figured out a few triggers to the symptoms, but often, theres no rhyme or reason to why I flare. Often, there is no visible sign of the war inside my body. I need your support.

RA causes inflammation that affects all parts of my body, but the way it hits my joints is the most obvious symptom. Im sure youve seen my sausage fingers or noticed the time my knee swelled to the size of a volleyball. Its because the synovial membrane that protects my joints becomes inflamed.

And it hurts.

I thought I knew what it meant to have pain before. We have all had some lower back pain after moving to a new house, a sprained ankle, and maybe even broken a bone. None of those kinds of pain is like the pain of RA. When my joints swell, it can feel as if the bones are being pried apart. When the inflammation gets bad, it throbs to the rhythm of my heart and any weight or pressure is excruciating. Every step feels like walking barefoot on rocks, typing for a while means I cant use my hands later, and it can make it hard to do the simplest of tasks. Like dressing myself, squeezing the shampoo bottle, or chopping vegetables.

Yes, I know everyone is tired. But this kind of tired doesnt get better with rest. The fatigue that comes with having RA is always there, utterly soul-crushing, and it doesnt matter if I get two hours of sleep at night or 12. Im still tired. My body is in a constant state of inflammation and keeps trying to get me to go lie down until I get better.

The problem is, I dont get better.

I wake up with less energy than I had before and everything I do takes more energy than it used to. The Spoon Theory is a really good way to explain how careful I have to be about what I do and why sometimes, I have to crawl into bed before dinner. Think of measuring energy by the spoonful. I start the day with a handful of spoons that are taken away, one by one, as I do tasks like getting dressed, doing chores, or working. Most days, I have no spoons left at the end of the day.

I used to only see my doctor a few times a year. Now, I have medical appointments all the time. Blood tests, X-rays, ultrasounds, appointments with my family doctor (because RA makes it easier for me to catch colds and the flu), and regular appointments with my rheumatologist, who oversees my RA treatment.

I am taking medication to suppress this condition, to protect my joints and the rest of my body against the constant inflammation. Please dont try to persuade me to go off the meds because you think the chemicals are bad for me. Its really hard to take this much medication every day, and sometimes, it has side effects. But it does beat down my RA most of the time and I want thatI cant live my life without them.

Some of the medication I take may include one that suppresses my immune system, and therefore suppresses my RA. This means I have a much higher risk of infection and catching contagious illnesses. One of the best ways you can help me is by getting the flu shot and not coming over when youre sick. Between the RA and being on these drugs, if I get sick, it might hit me harder and take a lot longer for me to get better.

Everything about my life has changed and I am having a really hard time coping. I feel like the healthy me died and now instead, I have to learn to live in this body that has betrayed me. There are so many physical changes, so much time dedicated to medical appointments, and figuring out how to fit all of that into my life. Everything feels overwhelming.

I know Im not always coping well. To be honest, I am really sad and also really angry. Im doing my best to learn what to do so I can still be your family member and your friend, but Im struggling. I know its hard for you to understand it all and that its difficult watch me go through this. I need your help, but please dont try to fix me. Right now, the thing I need the most is your love, patience, and support. I need some hugsgentle ones, pleasesome laughs, and some practical help. A phone call or visit would be wonderful, maybe a freezer meal, a ride to the doctor, or help with some chores. But most of all, I need you to just listen and try to understand.

Original post:
Dear Loved Ones: This Is What RA Feels Like - HealthCentral.com

The results of a French study found favorable outcomes for COVID-19 patients with moderate to severe pneumonia treated with tocilizumab, a drug commonly prescribed to treat arthritis, according to reports.

The French CORIMUNO-TOCI trial was conducted by the public assistance-hospitals of Paris (AP-HP). The results have yet to be published, but the outcomes were reported in a press release and by various news outlets. It included patients who were hospitalized with COVID-19 moderate to severe pneumonia in intensive care or at high risk of requiring intensive care but did not need resuscitation upon admission. The study included 129 patients who were randomized to either usual treatment plus tocilizumab (n=65) or usual treatment alone (n=64). The main outcome measure was the need for ventilation or death at 14 daysfor which tocilizumab significantly reduced the risk.

The unpublished study will reportedly be submitted for journal publication. According to a press release, the researchers stated that the results must be peer-reviewed and confirmed in further trials, but given the emergent need created by the pandemic, they felt it was important to communicate the results.

CORIMUNO is exploring other medicines in COVID-19 patients, too, including sarilumab. Although both are anti-IL-6 drugs, tocilizumab is administered intravenously, while sarilumab is administered subcutaneously.

The results of a phase 2 trial studying sarilumab in COVID-19 patients found the drug was not beneficial for patients hospitalized but not on ventilators, according to results from Regeneron and Sanofi, who manufacture the drug.

The trial of sarilumab, manufactured and sold under the brand name Kevzara, was modeled off of a 21-person study in China of tocilizumab, which optimistically concluded that patients symptomsincluding feverwere significantly reduced and they were able to be discharged from the hospital. With these promising outcomes in mind, Regeneron and Sanofi moved rapidly to evaluate Kevzara in a prospective, randomized, placebo-controlled adaptively-designed U.S. Phase 2/3 trial, according to a press release from the companies.

Even in a pandemic setting, its both crucial and possible to obtain controlled data in adequately-sized trials to provide the evidence needed to inform optimal medical care, said George D. Yancopoulos, MD, PhD, co-founder, president, and chief scientific officer of Regeneron, in the release. Emerging evidence with Kevzara and other repurposed drugs in the COVID-19 crisis highlight the challenges of making decisions about existing medicines for new viral threats using small, uncontrolled studies. We await results of the ongoing Phase 3 trial to learn more about COVID-19, and better understand whether some patients may benefit from Kevzara treatment. In addition, there is an acute need for tailored approaches that specifically target this virus. To that end, Regeneron is rapidly advancing our targeted anti-SARS-CoV-2 antibody cocktail and we plan to initiate clinical trials in June.

The New York Times reported that Dr. Yancopoulos was not optimistic about the trial because the drugs in questioned were made to treat arthritis, not COVID-19.

Repurposing existing drugs has not had a history of success in the pharmaceutical industry, he reportedly said.

Here is the original post:
Are Arthritis Drugs the Holy Grail of the COVID-19 Pandemic? Trials Rush to Find Solutions - DocWire News

While there are drugs that help reduce the symptoms of rheumatoid arthritis in the joints, those medications can have unpleasant side effects in other parts of the body. An experimental new light-based system, however, is being designed to change that.

One of the problems with existing rheumatoid arthritis drugs lies in the fact that after they've been ingested or injected, they're distributed throughout (and are active within) the entire body. This means that if they're taken in the quantities needed to reduce inflammation of the joints, they may produce side effects such as stomach aches or insomnia.

If they could only become active when they were at the joints, then much smaller doses would be required, resulting in fewer side effects. That's where the new system comes in.

Developed by scientists at the University of North Carolina in Chapel Hill, it involves attaching an existing drug to specially-engineered vitamin B12 molecules. Those molecules are then loaded into red blood cells, which get injected into the bloodstream.

As long as those cells aren't subsequently exposed to long-wavelength tissue-penetrating laser light, the drug remains trapped and inactive within them for up to two hours. If a laser is held to the skin at an arthritic joint, however, even low levels of its light within that joint trigger the nearby B12 molecules to release their drug payload from within the red blood cells. As a result, the medication only kicks in once it's at the target joint.

In lab tests, the technology was successfully used to deliver the arthritis drug dexamethasone to the arthritic paws of mice. When compared to simply injecting pure dexamethasone straight into the bloodstream, the laser-activated system required a three-fold lower dose to achieve the same therapeutic effect.

"We hope that our drug delivery platform will better control drug delivery and decrease the amount of systemic exposure and off-target effects," says team member and doctoral candidate Emilia Zywot. "We envision that it will be useful for any drug that can be synthetically attached to our light-responsive system, making it amenable to applications beyond arthritis."

The abstract for a paper on the research was recently published in The FASEB Journal.

Source: Experimental Biology via EurekAlert

More here:
Laser light used in targeted treatment of arthritis - New Atlas

Dry eye and subclinical abnormalities in visual functions in patients with psoriatic arthritis (PsA) sine-psoriasis may be related to systemic inflammation, according to study results published in the Journal of Clinical Medicine.

In this noninterventional, cross-sectional study, the disease activity of patients aged 18 to 65 years with diagnosed PsA and no evidence of skin psoriasis (n=40) was assessed by an experienced rheumatologist; a healthy control group (n=35) was also included in the study. All patients received a standard ophthalmology exam, which included best-corrected visual acuity, ocular surface disease index questionnaire, Schirmer test, and tear film breakup time (BUT). Standard automated perimetry, spectral-domain optical coherence tomography, and fundus perimetry scans were performed in all patients.

Researchers evaluated 80 and 70 eyes from patients in the PsA group (72.5% women; mean age, 5214 years) and the healthy control group (60% women; 48.713.8 years) , respectively. The best-corrected visual acuity of patients in the PsA group and the healthy control group were similar, and an abnormal ocular surface disease index (OSDI) was observed in 60% of patients with PsA. Prevalence of dry eye was significantly greater in the PsA group compared with the healthy control group (P <.0001). Approximately 75% of patients in the PsA group (n=30) were definitively diagnosed with dry eye (39.9% with BUT <10 sec; 23.4% with Schirmer 5 mm; 36.7% with both BUT <10 sec and Schirmer 5 mm).

Researchers indicated a positive correlation between OSDI and erythrocyte sedimentation rate (ESR; r=0.6; P <.001), In terms of the Schirmer test values, a negative correlation was observed between the scale of wetness and ESR (r=-0.43; P =.007). Results from standard automated perimetry indicated a higher mean deviation and pattern standard deviation in the PsA group compared with the healthy control group (P <.0001 and P =.005, respectively). In addition, ESR and C-reactive protein (CRP) showed a positive association with pattern standard deviation (r=0.3 and r=0.4; P =.04 and P =.01, respectively), while CRP was also correlated with mean deviation (r=-0.4; P =.01). Patients with PsA and the control participants demonstrated a similar visual field index (range, 98%-100%).

Assuming that relevant signs of systemic disease may be revealed as abnormalities occurring in the eye, a clinical evaluation of retinal morphology and function should be performed in order to detect subclinical damage of the visual system early, the researchers advised. In addition, careful ophthalmologic examination of patients with PsA sine-[psoriasis] may produce valuable clinical information on disease activity status. Using either [standard automated perimetry] or [fundus perimetry] and [optical coherence tomography] assessment could allow the detection of early changes in visual function even before clinically detectable retinopathy. These ancillary tests may serve as a useful monitoring tool over the entire course of the disease.

Reference

Chimenti MS, Triggianese P, Salandri G, et al. A multimodal eye assessment in psoriatic arthritis patients sine-psoriasis: evidence for a potential association with systemic inflammation. J Clin Med. 2020;9(3):E719.

See original here:
Visual Functions in Psoriatic Arthritis Sine-Psoriasis May Be Linked to Systemic Inflammation - Rheumatology Advisor

As GlaxoSmithKline prepares Voltaren Arthritis Pain for a sizable prescription-to-OTC switch next month, a new pre-order promotion will donate to the Arthritis Foundation.

Through May 12, the official Voltaren OTC availabilityday in the U.S., customers can order the NSAID osteoarthritis gelto getfirst-day at-home delivery through GSK Consumer Healthcare e-commerce partners. Profits from the sales will go to the Arthritis Foundation.

The awareness-buildingand pre-order effort is underway as behind the scenes, GSK is fine-tuning Voltarens prescription to OTC priority launch marketing push that will include TV, print, radio, in-store, digital and social advertising.

FiercePharma Presents the Virtual eRegulatory Operations Summit

Join industry experts and learn how to build and manage cohesive, compliant, and timely electronic submissions through innovative technologies and seamless clinical documentation processes.

RELATED:GSK looks for another OTC allergy crossover hit in newly launched Flonase Sensimist

GSK has the benefit of lessons learned from the Flonase allergy nasal spray prescription to OTC launch several years ago, said Jissan Cherian, Voltaren marketing director.Many of the same executives are still at GSK Consumer Healthcarechief marketing officer Amardeep Kahlon, in fact, oversaw the Flonase switch in 2015and while e-commerce has changed since then, other strategies have carried over.

In-store promotions, for instance, will follow the Flonase lead and use custom display units to educate consumers at point of sale, Cherian said. The multi-channel and extensive ad campaign looks to beanother nod to the Flonase model.

The campaign will seek to expand the Voltaren audience based on GSK research that found osteoarthritis begins for some people in their 30s. Without revealing specific creative, Cherian said a range of ages and life stages will be featured and that the brand will look to establish itself as a movement brand. The Voltaren website will be a first-ever for arthritis patients, created to be user friendly for their specific hand movement issues, he said.

RELATED:GlaxoSmithKline's spinoff plan is hereand it may not be limited to consumer health

As we saw with Flonase, once it becomes over the counter, we have an opportunity to engage a very large patient population and thats exactly what we want to do with Voltaren, Cherian said.

The Arthritis Foundation partnership began with GSK approaching the group to share research and validate its thinking for Voltaren. Thatevolved into the current awareness promotion, with the pre-order and e-commerce idea becoming even more relevant as the COVID-19 pandemic and stay-at-home orders developed.

The rest is here:
GSK partners with Arthritis Foundation as it preps Voltaren for OTC switch - FiercePharma

If you suffer with arthritis, finding a supplement right for you isn't always the easiest task. There's a lot of pills and potions that claim to relieve you of your symptoms, but which ones really work?

Arthritis and other joint conditions affect around 10 million of us in the UK and contrary to popular beliefs, can affect people of all ages.

Osteoarthritis and rheumatoid arthritis are the two most common types and both include symptoms that will cause inflammation, occasional swelling and stiffness of the joints - which over time will become painful and reduce mobility.

Whether you're in the early spectrum of your arthritis or you're just looking for something to manage the pain, there are supplements out there to help and assist with symptoms in the long run.

Before taking any supplement it's always advised to consult with a medical professional first. We've listed top picks worth considering in our roundup below.

Solgar Boswellia Resin Extract capsules are great for many reasons, one being they're nice and inclusive - suitable for vegetarians, vegans and kosher approved.

Boswellia is also known as Indian frankincense, the active components in the extract are widely known for naturally having anti-inflammatory and analgesic properties, it's also been used to treat a number of inflammatory conditions across the globe for centuries.

Some studies have also shown that it may be able to slow the autoimmune process, thus helping to further prevent cartilage loss, which should allow for more freedom in movement that can be comfortably enjoyed.

Price: 15.99, Amazon - buy here now

These supplements are specially formulated for women and are packed full of anti-inflammatory ingredients that will make you feel better from the inside out - at 7 a pop it's not a bad asking price either.

The four main active ingredients in the formula are cayenne, capsicum extract, tumeric and bioperine. Cayenne, capsicum extract, tumeric are all known for their anti-inflammatory and pain reducing properties, whilst the bioperine helps the nutrients to be properly absorbed.

Not only are results seen in the short term, long term pain is reportedly decreased with consistent use too. The tablets are suitable for vegans and vegetarians.

Price: 7, Amazon - buy here now

Cats Claw Cats claw contains a host of active ingredients that can benefit the immune system and overall health.

It's been widely credited by a number of sources to help with joint pain in the long run compared to some of the heavier placebos used to treat inflammatory conditions.

Price: 9.99, Holland and Barrett - buy here now

S-adenosylmethionine, or the lesser mouthful of SAM-e is a natural pain reliever with anti-inflammatory properties, making it a top contender for treating joint related pains.

As well as producing cartilage growth, it's also suggested to affect transmitters that ultimately reduce pain perception, which could be a great benefit for alleviating discomfort long term when it comes to activity.

Price: 18.13, iHerb - buy here now

If you're not ready to give up activity just yet, it's good practice to replenish what you're losing.

Our bodies naturally create glucosamine and chondroitin, they're what form all of the cartilage components, cartilage absorption in the early stage of arthritis is what you'll want to repair and rejuvenate in order to comfortably move around.

If you're running, doing intense training or any activities that might need a little bit of absorption on impact.

Price: 16.55, My Protein - buy here now

The active ingredient in tumeric is curcumin, curcumin has been popular for centuries and is known for its range of health benefits.

Curcumin however, isn't easily absorbed in the body - this fast acting formula from Opti, combines Curcumin with vitamin C in a highly absorbable formula that's hard working, seven times more so than powdered tumeric.

It's a great combination for supporting cartilage formulation and overall joint health.

Price: From: 10.95, Health Span - buy here now

Another hard working duo, these High Strength Glucosamine & Chondroitin Complex capsules help with the overall production of the cartilage and joint tissue, promoting overall joint and immune health.

These tablets also contain MSM, which is a a natural form of organic sulphur that further aids the bodys production of natural glycosaminoglycans.

Price: 12.99, Holland and Barrett - buy here now

If you're looking for the dream trio of anti-inflammatory properties - this supplement from FSC is it.

Ginger is thought to have similar effects to taking an ibruprofen and is used as a home remedy to treat a number of painful ailments.

Packed full of antioxidants and quick-absorbing nutrients that help to promote healing, relieving pain and reducing inflammation in the joints.

The supplement is suitable for vegans.

Price: 9.99, Amazon - buy here now

Fish oil is regularly used as a supplement to treat joint stiffness and inflammation.

Containing 360mg of active EPA/DHA with 25g of vitamin D3, the EPA and DHA are high in Omega-3 - good, fatty acids.

These compounds are converted by our bodies, into powerful chemicals called resolvins which are natural anti-inflammatories, that we just need a bit of help to produce.

Price: 19.99, Holland and Barrett - buy here now

To give yourself and your immune system a fighting chance against sickness, check out the best probiotic supplements to try in 2020.

Originally posted here:
Best supplements for arthritis to try in 2020 - Mirror Online - Mirror Online